Not applicableLooking for participantsNCT07621419
What this trial is testing
Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin
Who this might be right for
Diabetes Mellitus
Hospital Italiano de Buenos Aires 145